An apparent leak prompted Merck and Moderna to release the full trial results ahead of schedule, but investors puzzlingly greeted the good news by sending the companies’ stock prices down.
The vaccine, called intismeran, is tailored to each patient’s tumour. The science behind the cancer drug is based on Nobel Prize-winning mRNA technology, which was also behind Covid-19 vaccines.